Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712603 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket
CD ROMAdd to Basket
Electronic (PDF)Add to Basket
Site LicenseAdd to Basket
EnterprisewideAdd to Basket



Best Practices for Post-Marketing Surveillance of Adverse Events within the U.S.
Best Practices LLC, Sep 2009, Pages: 37


  Description  
  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

Medical and scientific progress has been enormous in the past decades. However, this has also raised several safety issues leading to increased vigilance on bio-pharma companies by the U.S. Food and Drug Administration Authority. Under such circumstances, it is imperative for the bio-pharmaceutical industry to maintain a dynamic post-marketing surveillance system to ensure regulatory compliance.

This benchmarking study examines the best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training.

Executives and managers in Drug Safety can use this research to compare their group's staffing, makeup, AE evaluation process, reporting sources, follow-up activities and training with those of leading organizations.

Study Snapshot:

This benchmarking report examines the best practices for post-marketing surveillance within the United States, as well as the processes for assessing reports of adverse events, follow-up activities and compliance training. Executives and managers in Drug Safety can use this research to compare their group's staffing, makeup, AE evaluation process, reporting sources, follow-up activities and training with those of leading organizations. Representatives from 15 leading companies have shared their practices, views and information, to facilitate post-market surveillance system. Following are the key topics covered in this report:

- Staffing and Workflow
- Drug Safety Processes and Reporting Sources
- Approach to AE Reports from Non-Traditional Sources
- Approach to AE Reports on Another Manufacturer’s Product
- Drug Safety Compliance Training
- Marketing Program Involvement
- Drug Safety Challenges

Industries Profiled:

- Pharmaceutical
- Health Care
- Biotech
- Service

Key Findings:

Staff Resources and Makeup: 80 percent of companies use physicians to review adverse event (AE) reports, more than 50 percent of benchmark partners also use pharmacists and nurses as reviewers.

- Post-Marketing Surveillance Process: Some drug safety activities appear common in the industry, such as outsourcing low-level work and forwarding all AE reports of other manufacturers. Nearly 60 percent of the benchmark class outsource low-level work such as data entry within their drug safety groups.

- Post-Marketing Adverse Events Reporting: Most of the companies said they report from a list of varied sources, 50 percent said they do not report from non-traditional sources such as blogs and interactive Web events.




Top of page


   All rights reserved. © Copyright 2010 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds